David Geffen
Optometrist · San Diego, CANPI 1164503678
Payments from drug & device makers
Across 491 payments — averaging $781.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$120K
- Bausch & Lomb Americas Inc.$90K
- AbbVie$48K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$44K
- Alcon$27K
- Topcon Corporation$26K
- plus $28K from 28 others
Across 2 payments — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Topcon Healthcare Solutions, Inc.$5K
What the payments were for
- Consulting fees$24,44017%
- Speaking & faculty fees$81,88557%
- Travel & lodging$18,67713%
- Food & beverage$19,07813%
- Entertainment$3330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 12 | $120,215 |
| Bausch & Lomb Americas Inc. | 131 | $90,467 |
| AbbVie(2 entities) | 6 | $47,847 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 86 | $44,192 |
| Alcon | 103 | $26,831 |
| Topcon Corporation | 1 | $26,475 |
| Shire North American Group Inc | 19 | $7,842 |
| Sun Pharmaceutical Industries Inc. | 25 | $6,709 |
| Novartis | 13 | $3,948 |
| Glaukos Corporation | 16 | $1,981 |
| Tarsus Pharmaceuticals, Inc. | 18 | $1,435 |
| Optovue, Inc. | 5 | $1,294 |
| Kala Pharmaceuticals, Inc. | 5 | $765 |
| Biotissue Holdings Inc. | 5 | $646 |
| Optos, Inc. | 5 | $444 |
| Harrow Eye, LLC | 10 | $388 |
| Coopervision Inc. | 3 | $272 |
| Lombart Brothers, Inc. | 1 | $239 |
| Sight Sciences, Inc. | 2 | $237 |
| Thea Pharma Inc. | 2 | $209 |
| Oculus, Inc. | 1 | $190 |
| Oyster Point Pharma, Inc. | 7 | $188 |
| Ivantis, Inc | 1 | $146 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $138 |
| Mallinckrodt Enterprises LLC | 1 | $138 |
| LKC Technologies, Inc. | 1 | $106 |
| Carl Zeiss Meditec, Inc. | 1 | $105 |
| Dompe US, Inc. | 3 | $99 |
| Tearlab Corp | 1 | $83 |
| Topcon Healthcare Solutions, Inc. | 1 | $75 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| Rxsight Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFUSE$40,860
- DAILIES$20,702
- BIOTRUE$19,513
- ULTRA$19,407
- XIIDRA$12,425
- BIOTRUE ONE DAY$11,321
- ZEN LENS$10,270
- ULTRA MULTIFOCAL TORIC$9,487
- CEQUA$6,081
- INFUSE MULTIFOCAL$4,232
- MIEBO$1,270
- iVue$1,250
- ZENLENS$1,025
- CE-marked KXLA system$825
- EYSUVIS$700
- PANORAMIC OPHTHALMOSCOPE$666
- OCT OPHTHALMOSCOPE$666
- KXL System$634
- iDoseTR$400
- iStent Infinite$400
How this compares
$383,770 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 24 | $20,653 |
| Loteprednol Etabonate | 14 | $1,787 |
| Latanoprost | 32 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $47,847 | $20,65324 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $44,192 | $1,78714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,778 optometrist providers in California.
Other optometrist in San Diego
- Keith WanSan Diego$887K
- Jason TuSan Diego$351K
- Dorothy WangSan Diego$312K
- Alicia LauSan Diego$300K
- Melody TavakoliSan Diego$267K
- Brian ChouSan Diego$243K
- Eric WhiteSan Diego$211K
- Elliott ShapiroSan Diego$135K
- Brittany McMurrenSan Diego$80K
- Meng LinBerkeley$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.